A 10 mg THC Brownie Changed Subjective Effects Without Detectable Task Deficits

In a small crossover trial, a 10 mg THC brownie produced subjective drug effects without significant performance deficits on the tested tasks compared with placebo. Higher doses impaired performance. The 10 mg finding is an endpoint-specific null result, not proof that this dose is safe for every person or activity.

Participants served as their own controls

The study involved 17 healthy adults who used cannabis infrequently. Each completed separate sessions with brownies containing 0, 10, 25 or 50 mg THC, with at least one week between sessions. The randomized, blinded comparison reduced the influence of stable differences between people.

Investigators collected repeated blood samples and assessed subjective effects, cardiovascular responses and cognitive or psychomotor performance. The tasks included divided attention, digit-symbol substitution and paced serial addition. These laboratory outcomes were not a direct driving test.

The dose pattern was not all-or-nothing

The 10 mg dose significantly increased ratings of drug effect and good drug effect relative to placebo. It also increased heart rate. Yet performance on the tested tasks did not significantly differ from placebo at that dose.

The 25 and 50 mg conditions produced performance deficits on multiple measures, with the detailed pattern varying by task and endpoint. Blood pressure did not show a significant overall dose effect. Reporting only “THC impaired cognition” would omit the lower-dose null finding; reporting only that null would omit measurable drug effects and the higher-dose results.

Why the null is not a safety guarantee

Seventeen participants cannot establish equivalence across all users, products and activities. The study selected healthy infrequent users and administered prepared brownies under controlled conditions. Other formulations, food conditions, concurrent drugs and individual susceptibility may change responses.

A subjective high, a blood concentration and a performance score are different observations. None should silently replace another. The delayed effects of oral cannabis also mean that an early observation may not characterize the entire session.

For forensic interpretation, retain the dose, route, sampling time and actual functional evidence. Our article on THC concentration and impairment addresses why a numerical result alone cannot determine a person’s condition at an earlier event.

Primary research

Nicolas J. Schlienz and colleagues. Drug and alcohol dependence (2020). Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us